Person: Buño Borde, Ismael
Loading...
First Name
Ismael
Last Name
Buño Borde
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Medicina
Department
Biología Celular
Area
Biología Celular
Identifiers
3 results
Search Results
Now showing 1 - 3 of 3
- Project number: 214
Item El formato vídeo como herramienta docente y estrategia para el aprendizaje activo de la genética: el análisis de su idoneidad como un paso indispensable para su posible implementación() Sacedón Ayuso, Rosa; Jiménez Pérez, Eva; Buño Borde, Ismael; Zuluaga Arias, Pilar; Orera Clemente, María Asunción; Pujol de Castro, Antonio; Escribano Martínez, Catalina; Rodríguez Sánchez, Belén; Muñoz Delgado, CeciliaEn el presente proyecto hemos preparado material docente y propuesto una actividad para los alumnos, ambos en formato vídeo. Tras ello, a través de una encuesta a los estudiantes participantes, hemos analizado su idoneidad como estrategias para el aprendizaje de la Genética en Medicina, identificando sus puntos fuertes y débiles. - Project number: 443
Item El formato vídeo como herramienta para el aprendizaje de la Histología. Implementación de “HistoApp” para la autoevaluación individual y asistida del alumno como refuerzo para el aprendizaje(2023) Buño Borde, Ismael; Sacedón Ayuso, Rosa; Novillo Villajos, Apolonia; Jiménez Pérez, Eva; Zuluaga Arias, María Del Pilar; Escribano Martínez, Catalina; Orera Clemente, María Asunción; Ortega Salmerón, Lucía; Buño Borde, Ismael Item Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy(Cancers, 2023) Rodríguez-Macías, Gabriela; Briz, Oscar; Cives-Losada, Candela; Chillón, María; Martínez-Laperche, Carolina; Martínez-Arranz, Ibon; González-Díaz, Marcos; Marin, Jose; Macias, Rocio; Buño Borde, Ismael; Díez Martín, José LuisDespite its often low efficacy and high toxicity, the standard treatment for acute myeloid leukemia (AML) is induction chemotherapy with cytarabine and idarubicin. Here, we have investigated the role of transporters and drug-metabolizing enzymes in this poor outcome. The expression levels (RT-qPCR) of potentially responsible genes in blasts collected at diagnosis were related to the subsequent response to two-cycle induction chemotherapy. The high expression of uptake carriers (ENT2), export ATP-binding cassette (ABC) pumps (MDR1), and enzymes (DCK, 5-NT, and CDA) in the blasts was associated with a lower response. Moreover, the sensitivity to cytarabine in AML cell lines was associated with ENT2 expression, whereas the expression of ABC pumps and enzymes was reduced. No ability of any AML cell line to export idarubicin through the ABC pumps, MDR1 and MRP, was found. The exposure of AML cells to cytarabine or idarubicin upregulated the detoxifying enzymes (5-NT and DCK). In AML patients, 5-NT and DCK expression was associated with the lack of response to induction chemotherapy (high sensitivity and specificity). In conclusion, in the blasts of AML patients, the reduction of the intracellular concentration of the active metabolite of cytarabine, mainly due to the increased expression of inactivating enzymes, can determine the response to induction chemotherapy.